Retrospective cohort study of Qi Zhen Yi Liu Formula and somatostatin analogues in advanced pan-creatic neuroendocrine tumors
Abstact Objective:To explore the advantages of Qi Zhen Yi Liu formula combined with somatostatin analogs(SSAs)in treating advanced pancreatic neuroendocrine tumors(PanNETs).Methods:A retrospective analysis was conducted on the medical records of patients with advanced PanNETs treated with Qi Zhen Yi Liu formula and/or SSAs at China-Japan Friendship Hospital from August 2012 to June 2023.The analysis focused on treatment efficacy,safety,and factors influencing progression-free survival(PFS).Results:The median PFS for the Qi Zhen Yi Liu formula group(n=5)was not reached due to insufficient follow-up time,while the SSA group(n=7)had a median PFS of 7.97 months(95％CI:7.63,8.30),and the combined treatment group(n=44)had a median PFS of 25.00 months(95％CI:22.02,27.99).The integrated treatment of traditional Chinese and western medicine significantly improved the disease control rate.Liver tumor burden,Ki-67 index,and whether the primary tumor was surgically removed were independent factors affecting PFS(P＜0.05).Conclusion:The combination of Qi Zhen Yi Liu formula and SSAs in treating advanced PanNETs can prolong PFS,reduce SSA-related adverse reactions and improve quality of life.This combination treatment is particularly effective in patients with a lower liver tumor burden,lower Ki-67 index,and those who have undergone surgical remov-al of the primary tumors.
pancreatic neuroendocrine tumorsQi Zhen Yi Liu formulasomatostatin analogsprogression-free survival
NETL
NSTL
万方数据
